Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms LP 103 |
Target |
Action stimulants |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Myeloma | Preclinical | China | 07 Nov 2021 | |
| Stomach Cancer | Preclinical | China | - |






